title: Asthma variability in patients previously treated with beta2-agonists alone.
abstract: BACKGROUND
  According to national asthma guidelines, asthma severity can be classified as intermittent, mild, moderate, or severe on the basis of lung function, symptoms, nighttime awakenings, and exacerbations. Although it is widely believed that patients might not remain consistently in any given severity category over time, few studies have examined this directly.
  
  
  OBJECTIVE
  We sought to assess the variability in disease severity-control among patients with persistent asthma who have not yet received an asthma maintenance treatment.
  
  
  METHODS
  We performed an analysis of asthma severity-control over time in placebo-treated patients (n = 85) from 2 randomized, double-blind, 12-week clinical trials in patients with asthma previously receiving beta(2)-agonists alone. Asthma severity-control was assessed on the basis of morning percent predicted peak expiratory flow, albuterol use, and symptoms.
  
  
  RESULTS
  At baseline, all patients met the criteria for moderate or severe persistent asthma (mean FEV(1) of 64% of predicted value or albuterol use and symptoms on 4.7 and 6.0 days per week, respectively). The mean percentage of treatment weeks that patients met all criteria for intermittent, mild, moderate, and severe asthma were 9%, 14%, 71%, and 6%, respectively. On the basis of morning peak expiratory flow, patients were classified as having intermittent-mild, moderate, or severe disease on 52%, 41%, and 7% of days, respectively. With regard to days per week with albuterol use or asthma symptoms, patients spent 59% and 45% of weeks, respectively, in the intermittent and mild categories.
  
  
  CONCLUSIONS
  Asthma control cannot be adequately assessed in many patients by using discrete point-in-time assessments of lung function, short-acting beta-agonist use, or asthma symptoms. This might lead to underestimation of disease severity and contribute to inadequate therapy and, ultimately, asthma morbidity.
authors.affiliation: Division of Pulmonary Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
authors.forename: William J
authors.initials: WJ
authors.lastname: Calhoun
authors.forename: Laura B
authors.initials: LB
authors.lastname: Sutton
authors.forename: Amanda
authors.initials: A
authors.lastname: Emmett
authors.forename: Paul M
authors.initials: PM
authors.lastname: Dorinsky
mesh_terms: D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000730:Androstadienes / Q000627:therapeutic use*; D001249:Asthma / Q000145:classification* / Q000175:diagnosis* / Q000188:drug therapy; D002648:Child; D019468:Disease Management; D004338:Drug Combinations; D005260:Female; D000068297:Fluticasone-Salmeterol Drug Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index
chemical_list: D000318:Adrenergic beta-Agonists; D000730:Androstadienes; D004338:Drug Combinations; D000068297:Fluticasone-Salmeterol Drug Combination; D000420:Albuterol